- Home
- ICU vs AIDX Comparison
ICU vs AIDX Comparison
Compare ICU & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | AIDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ICU | AIDX |
|---|---|---|
| Price | $3.82 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 70.5K | ★ 217.3K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.90 |
| 52 Week High | $5.10 | $14.09 |
Technical Indicators
Market Signals| Indicator | ICU | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 17.71 |
| Support Level | $3.72 | N/A |
| Resistance Level | $4.96 | $1.66 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 18.75 | 9.12 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.